Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Study of Lolatinib for Patients With Advanced/Metastatic Anaplastic Lymphoma Kinase (ALK) - Positive Non-Small Cell Lung Cancer (NSCLC)

NCT06361589 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT06361589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06361589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Study of Lolatinib for Patients With Advanced/Metastatic Anaplastic Lymphoma Kinase (ALK) - Positive Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Observational
Overall status
Recruiting
Start date
May 1, 2024
Completion date
November 1, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non-small cell lung cancer, real world study